Healthcare / Biotech
Beam Therapeutics
30-Second Executive Brief
Executive Assessment
Beam Therapeutics functions as an established institution within Healthcare / Biotech, backed by 17% sourcing coverage, with a stable competitive position.
- Maintains 3 mapped relationships across the graph
- 17% sourcing coverage across sourced relationships
- Tracked as established institution within the Healthcare / Biotech category
Executive Snapshot
- Strategic Role
- Established Institution
- Sourcing Coverage
- 17%
- Ecosystem Influence
- High
- Strategic Momentum
- Insufficient Data
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 3
- Technology Domains
- 3
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
Precision genetic medicine company pioneering base editing technology. Beam Therapeutics announced the first patient dosed in the global pivotal cohort of its BEAM-302 trial for alpha-1 antitrypsin deficiency (AATD) in Q2 2026, and presented updated Phase 1/2 BEAM-302 data in a late-breaking oral presentation at the European Respiratory Society Congress 2026.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
1 source
- Beam Therapeutics — Beam Therapeutics doses first patient in BEAM-302 pivotal cohortcompany
Latest Activity
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Beam Therapeutics — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
Beam Therapeutics's Timeline
A sourced, dated history of Beam Therapeutics's key moments — founding to present.
Jan 2026 · Doses first patient in BEAM-302 pivotal cohort
Beam Therapeutics announced the first patient dosed in the global pivotal cohort of its BEAM-302 trial for alpha-1 antitrypsin deficiency (AATD).